Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TARS1 | P26639 | 2/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.37 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30674291 | 1.00 | TARS1 (0.37) | TARS1ADORA3SLC29A1ADORA1ADORA2A | |
| SCHEMBL30379388 | 0.95 | ADORA3 (0.37) | ADORA3SLC29A1ADORA1ADORA2A | |
| SCHEMBL2033389 | 0.90 | ADORA1 (0.38) | TARS1ADORA3SLC29A1ADORA1ADORA2A | |
| SCHEMBL30037173 | 0.90 | ADORA1 (0.38) | TARS1ADORA3SLC29A1ADORA1ADORA2A | |
| SCHEMBL17371759 | 0.88 | TARS1 (0.37) | TARS1SLC29A1ADORA1 | |
| SCHEMBL27641587 | 0.85 | SLC29A1 (0.38) | ADORA3SLC29A1ADORA1ADORA2A | |
| SCHEMBL29089525 | 0.83 | TARS1 (0.39) | TARS1SLC29A1ADORA1 | |
| SCHEMBL16987222 | 0.81 | TARS1 (0.38) | TARS1SLC29A1ADORA1 | |
| SCHEMBL28564130 | 0.81 | TARS1 (0.38) | TARS1SLC29A1ADORA1 | |
| SCHEMBL29435121 | 0.81 | TARS1 (0.38) | TARS1SLC29A1ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4379052-A2 | MRNA PURIFICATION BY TANGENTIAL FLOW FILTRATION | Ethris GmbH (DE) | 2024-06-05 | — | — | EP | claimed |
| US-12612658-B2 | RNA replication using transcription polymerases | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2026-04-28 | — | — | US | disclosed |
| US-20260071215-A1 | SYSTEMS FOR ENHANCING TARGET MRNA EXPRESSION AND USES THEREOF | UNIV JOHNS HOPKINS (US) | 2026-03-12 | — | — | US | disclosed |
| EP-3752610-B1 | POLYRIBONUCLEOTIDE CONTAINING DEUTERATED NUCLEOTIDES | ETHRIS GMBH (DE) | 2026-01-28 | — | — | EP | disclosed |
| US-12522821-B2 | Polyribonucleotide containing deuterated nucleotides | ETHRIS GMBH (DE) | 2026-01-13 | — | — | US | disclosed |
| US-12509679-B2 | mRNA purification by tangential flow filtration | ETHRIS GMBH (DE) | 2025-12-30 | — | — | US | disclosed |
| US-20250207163-A1 | METHODS AND APPARATUS FOR SYNTHESIZING NUCLEIC ACIDS | TRILINK BIOTECHNOLOGIES, LLC | 2025-06-26 | — | — | US | disclosed |
| EP-4553084-A2 | USE OF IFN-LAMBDA MRNA FOR TREATING VIRAL INFECTIONS | Ethris GmbH (DE) | 2025-05-14 | — | — | EP | disclosed |
| EP-4499824-A1 | METHODS AND APPARATUS FOR SYNTHESIZING NUCLEIC ACIDS | Molecular Assemblies, Inc. (US) | 2025-02-05 | — | — | EP | disclosed |
| EP-4240396-B1 | IFN-LAMBDA MRNA FOR TREATING VIRAL INFECTIONS | ETHRIS GMBH (DE) | 2025-01-01 | — | — | EP | disclosed |
| EP-3924487-A1 | MRNA PURIFICATION BY TANGENTIAL FLOW FILTRATION | ethris GmbH (DE) | 2021-12-22 | — | — | EP | disclosed |
| US-20210317179-A1 | PRECISELY ENGINEERED STEALTHY MESSENGER RNAS AND OTHER POLYNUCLEOTIDES | KERNAL BIOLOGICS, INC. | 2021-10-14 | — | — | US | disclosed |
| EP-3833360-A1 | PRECISELY ENGINEERED STEALTHY MESSENGER RNAS AND OTHER POLYNUCLEOTIDES | Kernal Biologics, Inc. (US) | 2021-06-16 | — | — | EP | disclosed |
| WO-2021007233-A1 | RNA REPLICATION USING TRANSCRIPTION POLYMERASES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2021-01-14 | — | — | WO | disclosed |
| US-20210009995-A1 | POLYRIBONUCLEOTIDE CONTAINING DEUTERATED NUCLEOTIDES | ETHRIS GMBH (DE) | 2021-01-14 | — | — | US | disclosed |
| EP-3752610-A1 | POLYRIBONUCLEOTIDE CONTAINING DEUTERATED NUCLEOTIDES | ethris GmbH (DE) | 2020-12-23 | — | — | EP | disclosed |
| WO-2020165158-A1 | MRNA PURIFICATION BY TANGENTIAL FLOW FILTRATION | ETHRIS GMBH (DE) | 2020-08-20 | — | — | WO | disclosed |
| WO-2020165352-A1 | TREATMENT OF CILIOPATHIES | ETHRIS GMBH (DE) | 2020-08-20 | — | — | WO | disclosed |
| WO-2020033720-A1 | PRECISELY ENGINEERED STEALTHY MESSENGER RNAS AND OTHER POLYNUCLEOTIDES | KERNAL BIOLOGICS, INC. (US) | 2020-02-13 | — | — | WO | disclosed |
| WO-2019158583-A1 | POLYRIBONUCLEOTIDE CONTAINING DEUTERATED NUCLEOTIDES | ETHRIS GMBH (DE) | 2019-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12509679-B2 | mRNA purification by tangential flow filtration | ELL, RNGTT, FIP1L1 | TARS1 2357/4885ADORA3 2581/4885SLC29A1 1244/4885 |
| US-20260071215-A1 | SYSTEMS FOR ENHANCING TARGET MRNA EXPRESSION AND USES THEREOF | UPF1, RBM26, RPRD2 | TARS1 435/4885ADORA3 2047/4885SLC29A1 389/4885 |
| US-12612658-B2 | RNA replication using transcription polymerases | RNGTT, POLRMT, POLM | TARS1 755/4885ADORA3 238/4885SLC29A1 2504/4885 |
| US-20250207163-A1 | METHODS AND APPARATUS FOR SYNTHESIZING NUCLEIC ACIDS | RNGTT, POLRMT, POLN | TARS1 751/4885ADORA3 1331/4885SLC29A1 358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.